Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Mabwell Bio of Shanghai Closes $278.5 Million Series A Financing

publication date: Apr 29, 2020

Mabwell Biotech, based in Shanghai's Zhangjiang Hi-Tech Park, raised an impressive $278.5 million in a Series A round. Founded in 2017, the company has absorbed or started nine biopharmaceutical R&D and production companies. Mabwell focuses on developing large molecule drugs including mAbs and long-acting recombinant proteins, building a portfolio of more than thirty candidates that target oncology, autoimmune, infectious and ophthalmic diseases. So far, it has started clinical trials for six candidates, three of which are being tested in Phase III trials. It hopes to launch its first product this year. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital